1921
Volume 96, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Coinfection with visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) leads to frequent treatment failure, relapse, and death. In this retrospective analysis from eastern India (2005–2015), our primary objective was to ascertain the protective efficacy of secondary prophylaxis with monthly amphotericin B (AmB) given in patients with HIV–VL coinfection toward reducing relapse and mortality rates. The secondary objective was to compare clinical features, laboratory findings, and treatment outcomes in HIV–VL patients in contrast to VL monoinfection. Overall, 53 cases of HIV–VL and 460 cases of VL monoinfection were identified after excluding incomplete records. Initial cure rate was 96.23% in HIV–VL (27 received liposomal AmB and 26 AmB deoxycholate). All patients with initial cure ( = 51) were given antiretroviral therapy. Secondary prophylaxis ( = 27) was provided with monthly 1 mg/kg AmB (15 liposomal, 12 deoxycholate). No relapse or death was noted within 6 months in the secondary prophylaxis group (relapse: none versus 18/24 [75%]; mortality: none versus 11/24 [45.8%]; < 0.001 for both). Secondary prophylaxis remained the sole significant predictor against death in multivariate Cox regression model (hazard ratio = 0.09 [95% confidence interval = 0.03–0.31]; < 0.001). HIV–VL patients had higher 6-month relapse rate, less relapse-free 12-month survival, and higher mortality ( < 0.001 each) than VL monoinfection. In conclusion, it appears from this study that secondary prophylaxis with monthly AmB might be effective in preventing relapse and mortality in HIV–VL.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0432
2017-02-08
2018-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/2/285.html?itemId=/content/journals/10.4269/ajtmh.16-0432&mimeType=html&fmt=ahah

References

  1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team; , 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.[Crossref]
  2. Singh SP, Reddy DC, Rai M, Sundar S, , 2006. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 11: 899905.[Crossref]
  3. Directorate of National Vector Borne Disease Control Programme, 2014. National Roadmap for Kala-Azar Elimination in India. Delhi, India.
  4. National AIDS Control Organization, 2014. State Fact Sheets. Delhi, India: Department of AIDS Control, Ministry of Health and Family Welfare, Government of India.
  5. UN Joint Programme on HIV/AIDS (UNAIDS), 2014. The Gap Report. Available at: http://www.refworld.org/docid/53f1e1604.html. Accessed September 25, 2015.
  6. Alexander J, Brombacher F, , 2012. T helper1/T helper2 cells and resistance/susceptibility to Leishmania infection: is this paradigm still relevant? Front Immunol 3: 80.[Crossref]
  7. Mock DJ, Hollenbaugh JA, Daddacha W, Overstreet MG, Lazarski CA, Fowell DJ, Kim B, , 2012. Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection. PLoS Pathog 8: e1002635.[Crossref]
  8. Jarvis JN, Lockwood DN, , 2013. Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 26: 19.[Crossref]
  9. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J, , 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334359.[Crossref]
  10. Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, Kumar S, Mitra G, Kumar R, Verma N, Das P, , 2014. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis 8: e3053.[Crossref]
  11. Cota GF, de Sousa MR, Fereguetti TO, Rabello A, , 2013. Efficacy of anti-Leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis 7: e2195.[Crossref]
  12. Goswami RP, Goswami RP, Das S, Satpati A, Rahman M, , 2016. Short-course treatment regimen of Indian visceral leishmaniasis with an Indian liposomal amphotericin B preparation (Fungisome™). Am J Trop Med Hyg 94: 9398.[Crossref]
  13. Sinha PK, Rabidas VN, Pandey K, Verma N, Gupta AK, Ranjan A, Das P, Bhattacharya SK, , 2003. Visceral leishmaniasis and HIV coinfection in Bihar, India. J Acquir Immune Defic Syndr 32: 115116.[Crossref]
  14. Thakur CP, Narayan S, Ranjan A, , 2003. Kala-azar (visceral leishmaniasis) and HIV coinfection in Bihar, India: is this combination increasing? J Acquir Immune Defic Syndr 32: 572573.[Crossref]
  15. Mathur P, Samantaray JC, Vajpayee M, Samanta P, , 2006. Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics. J Med Microbiol 55: 919922.[Crossref]
  16. Burza S, Mahajan R, Sanz MG, Sunyoto T, Kumar R, Mitra G, Lima MA, , 2014. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis 59: 552555.[Crossref]
  17. Goswami RP, Bairagi B, Kundu PK, , 2003. K39 strip test: easy, reliable and cost-effective field diagnosis for visceral leishmaniasis in India. J Assoc Physicians India 51: 759761.
  18. Goswami RP, Goswami RP, Das S, Ray Y, Rahman M, , 2012. Testing urine samples with rK39 strip as the simplest non-invasive field diagnosis for visceral leishmaniasis: an early report from eastern India. J Postgrad Med 58: 180184.[Crossref]
  19. Goswami RP, Rahman M, Guha SK, , 2007. Utility of K39 strip test in visceral leishmaniasis (VL) and HIV co-infected patients: an early report from eastern India. J Assoc Physicians India 55: 154155.
  20. Villanueva JL, Alarcón A, Bernabeu-Wittel M, Cordero E, Prados D, Regordán C, Alvar J, , 2000. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 19: 798801.[Crossref]
  21. Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A, , 2007. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 60: 837842.[Crossref]
  22. Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B, , 2000. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 14: 29462948.[Crossref]
  23. Casado JL, Lopez-Velez R, Pintado V, Quereda C, Antela A, Moreno S, , 2001. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 20: 202205.
  24. Cota GF, de Sousa MR, Rabello A, , 2011. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 5: e1153.[Crossref]
  25. Ribera E, Ocaña I, de Otero J, Cortes E, Gasser I, Pahissa A, , 1996. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 100: 496501.[Crossref]
  26. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E, , 2001. Visceral leishmaniasis in HIV-infected and non-HIV-infected patients: a comparative study. Medicine (Baltimore) 80: 5473.[Crossref]
  27. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, Lazzarin A, Uberti-Foppa C, Cinque P, , 2003. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 41: 50805084.[Crossref]
  28. López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejías ME, Górgolas M, Arribas JR, Salas A, Laguna F, Sust M, Cañavate C, Alvar J, Spanish HIV-Leishmania Study Group; , 2004. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 53: 540543.[Crossref]
  29. Delgado Fernández M, García Ordoñez MA, Martos Pérez F, Reguera Iglesias JM, Jiménez Oñate F, Colmenero Castillo JD, , 1997. The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection. Med Interna 14: 506510.
  30. Diro E, Ritmeijer K, Boelaert M, Alves F, Mohammed R, Abongomera C, Ravinetto R, De Crop M, Fikre H, Adera C, Colebunders R, van Loen H, Menten J, Lynen L, Hailu A, van Griensven J, , 2015. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study. PLoS Negl Trop Dis 9: e0004087.[Crossref]
  31. Harhay MO, Olliaro PL, Vaillant M, Chappuis F, Lima MA, Ritmeijer K, Costa CH, Costa DL, Rijal S, Sundar S, Balasegaram M, , 2011. Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, east Africa, and south Asia. Am J Trop Med Hyg 84: 543550.[Crossref]
  32. Mahajan R, Das P, Isaakidis P, Sunyoto T, Sagili KD, Lima MA, Mitra G, Kumar D, Pandey K, Van Geertruyden JP, Boelaert M, Burza S, , 2015. Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India. Clin Infect Dis 61: 12551262.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0432
Loading
/content/journals/10.4269/ajtmh.16-0432
Loading

Data & Media loading...

  • Received : 30 May 2016
  • Accepted : 19 Oct 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error